GI
MLYS icon

GAMMA Investing’s Mineralys Therapeutics MLYS Stock Holding History

GAMMA Investing’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Buy
515
+41
+9% +$1.13K ﹤0.01% 3039
2026
Q1 		$12.8K Buy
474
+23
+5% +$675 ﹤0.01% 2937
2025
Q4 		$16.4K Buy
451
+15
+3% +$602 ﹤0.01% 2718
2025
Q3 		$16.5K Sell
436
-1
-0.2% -$22 ﹤0.01% 2616
2025
Q2 		$5.91K Sell
437
-119
-21% -$1.72K ﹤0.01% 3057
2025
Q1 		$8.83K Buy
556
+465
+511% +$5.35K ﹤0.01% 2808
2024
Q4 		$1.12K Buy
91
+16
+21% +$209 ﹤0.01% 3392
2024
Q3 		$908 Buy
+75
New +$908 ﹤0.01% 3282

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GAMMA Investing's MLYS Position: Q2 2026 in Review

GAMMA Investing increased its Mineralys Therapeutics (MLYS) stake by 8.6% in Q2 2026, buying an estimated $1.13K and bringing the position to 515 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

GAMMA Investing first reported a position in MLYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.5K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • GAMMA Investing held 515 shares of Mineralys Therapeutics worth $13.9K as of Q2 2026.
  • GAMMA Investing bought 41 Mineralys Therapeutics shares in Q2 2026, an estimated $1.13K.
  • Mineralys Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3039 holding.
  • GAMMA Investing first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • GAMMA Investing's Mineralys Therapeutics position peaked at $16.5K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.